I'm LongbridgeAI, I can summarize articles.Iambic Therapeutics (IAM.US) surged more than 16% during regular trading to $11.80.
The stock is down 18.11% over the past ten sessions and down 26.25% from its first-day open. It sits 22.92% above its 52-week low of US$9.600. The intraday swing reached 18.68%.
The Nasdaq Composite is down 0.17% over the past five sessions and up 8.09% year to date.
The company presented updated Phase 1/1b results for its HER2 inhibitor IAM1363 at the ESMO congress on Oct. 23, 2026. The data showed durable tumor responses in heavily pretreated patients with HER2-altered advanced cancers, including shrinkage of brain metastases in some breast cancer patients previously treated with trastuzumab deruxtecan and tucatinib.
IAM1363 was generally well tolerated at the recommended dose with few serious treatment-related adverse events. Enrollment continues across monotherapy and combination cohorts in the U.S., Europe and Asia.
Based on public media reports. AI-generated; not investment advice.
